Detecting the presence/risk of cancer development in a mammal, comprises detecting the presence/absence or (relative) quantity e.g. of nucleic acids and/or polypeptides coded by the nucleic acids, which indicates the presence/risk

摘要

Detecting the presence/risk of cancer development in a mammal, comprises detecting nucleic acids (I) comprising one of (SEQ ID No. 23, 52, 53, 148 and 225) or a distinctive fragment having at least 15, preferably 16, 17, 18, 19, 20, 25 or 30 consecutive bases, nucleic acids (II) having a complementary sequence of (I), functional analogs (III) of (I) or (II) from an another species and/or polypeptides coded by (I)-(III), in a sample, where the presence/absence or (relative) quantity of the target molecules indicates the presence/risk of cancer development. Detecting the presence/risk of cancer development in a mammal, comprises detection of the nucleic acids (I) comprising one of 5 fully defined 30-102 amino acid sequences (SEQ ID No. 23, 52, 53, 148 and 225) (PANEL 11) given in the table 1 of the specification or a distinctive fragment of those having at least 15, preferably 16, 17, 18, 19, 20, 25 or 30 consecutive bases, the nucleic acids (II) having a complementary sequence of (I), the functional analogs (III) of (I) or (II) from an another species and/or the polypeptides coded by (I)-(III), in a biological sample of the mammal, where the presence, absence or (relative) quantity of the target molecules in the sample being an indication of the presence or risk of cancer development in mammal. Independent claims are included for: (1) an in vitro or ex vivo detection of the presence/risk of cancer development in a mammal, comprising the determination of the presence/absence of an alteration in a gene or RNA e.g. receptors, adapters, enzymes, factors involved in gene expression regulation, chemokines, cytokines or interleukines, i.e. the gene or RNA involved in the stimulation of toll-like receptors, secretion of cytokines or activation of T lymphocytes, in a biological sample of the mammal, preferably in a blood (derivative) sample, where the presence of such alteration indicates presence/risk of cancer development in mammal; (2) the use of a specific nucleic probe of target nucleic acids, comprising of 15-400 bases, for the in vitro detection of human cancer; (3) the use of a nucleic starter allowing the amplification of total or part of a target nucleic acid, being simple-strand, with a length range of 5-50 bases, for in vitro detection of human cancer; (4) a product comprising a support on which at least two probes are immobilized of distinct nucleic acids comprising a complementary and/or specific sequence from at least two distinct target nucleic acids comprising at least two sequences comprising one of 437 fully defined 30-500 amino acid sequences (SEQ ID No. 1-437) given in the specification or at least a gene or RNA indicated in the table 5 or 6, of the specification; and (5) a product comprising a support on which at least a set of two distinct nucleic acid probes comprising a complementary sequence and/or specific nucleic acids of the panels 1-11, are immobilized.